Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

IBRX - ImmunityBio, Inc.


2.96
-0.050   -1.689%

Share volume: 6,361,129
Last Updated: 04-01-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: -0.05%

PREVIOUS CLOSE
CHG
CHG%

$3.01
-0.05
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
32%
Profitability 25%
Dept financing 25%
Liquidity 74%
Performance 30%
Company vs Stock growth
vs
Performance
5 Days
-5.73%
1 Month
3.86%
3 Months
15.18%
6 Months
-17.09%
1 Year
-43.83%
2 Year
65.36%
Key data
Stock price
$2.96
P/E Ratio 
0.00
DAY RANGE
$2.92 - $3.26
EPS 
-$0.59
52 WEEK RANGE
$2.28 - $10.53
52 WEEK CHANGE
-$48.16
MARKET CAP 
1.784 B
YIELD 
N/A
SHARES OUTSTANDING 
696.533 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
2.82
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$7,309,306
AVERAGE 30 VOLUME 
$5,861,070
Company detail
CEO: Richard Adcock
Region: US
Website: immunitybio.com
Employees: 590
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers.

Recent news